Doximity has not finished its decline, according to the charts.
Let's look at the charts and indicators.
Let's look at the charts of the biotech.
Let's check the charts on this biotechnology stock and see if it still has a prayer.
Here's our fresh take on the shares.
Patient investors could go long KN at current levels.
The shares have been cut in half over the last six months.
Here's how traders can play the stock.
Traders could go long ISRG at current levels.
Stand aside and let things "shake out".